Jon Hamilton

At a scientific meeting in Denver, Colo., doctors who treat Alzheimer's patients are figuring out how they will use the newly approved drug Aduhelm, which has had conflicting evidence of its efficacy.

Some patients who have had COVID-19 develop symptoms resembling early Alzheimer's. Researchers are trying to figure out whether these people are more likely to develop the disease itself.

A stroke left a man paralyzed and speechless. Now a device that decodes brain signals is letting him generate words and sentences.

A plaque-busting Alzheimer's drug called Aduhelm has yet to prove it can preserve memory and thinking. Even so, its approval by the Food and Drug Administration is making some patients opitimistic.

After a stroke, people often lose dexterity in one hand. Now, the Food and Drug Administration has authorized a device that can restore function by encouraging the brain to rewire.

Many scientists have criticized the FDA for approving Aduhelm, a costly Alzheimer's drug that may not do much to slow the disease. But a patient taking the drug says it has given him hope.

A newly approved drug for Alzheimer's disease will costs tens of thousands of dollars a year, and there is debate on whether it will help patients at all.

This is the first new drug approved for Alzheimer's disease since 2003. It's the first to show significant progress against the sticky brain plaques that are the hallmark of Alzheimer's disease.

The FDA has until Monday to decide whether to approve the first new Alzheimer's drug in nearly two decades. Two big studies of the drug produced conflicting results.

The FDA is poised to decide whether to approve aducanumab, a drug to treat Alzheimer's. It's proved highly effective at removing the sticky amyloid plaques associated with the disease from the brain.

Stroke patients who are struggling to regain the use of a hand will soon have access to a new FDA-cleared device that uses signals from the undamaged part of the brain to retrain the injured limb.

A man who is paralyzed can quickly perform tasks like pouring a glass of water, thanks to a mind-controlled robotic arm that conveys a sense of touch.

A robotic arm with a sense of touch has allowed a man who is paralyzed to quickly perform tasks like pouring water into a cup. The arm provides sensory information directly to the man's brain.

By decoding the brain signals involved in handwriting, researchers have allowed a man who is paralyzed to transform his thoughts into words on a computer screen.

The nation's top addiction scientist has teamed up with a prominent artist to let people know that substance use disorder is a disease, not a moral failure.

An experimental medicine seems to ease symptoms of Fragile X syndrome, a genetic disorder that is the most common inherited cause of intellectual disabilities and autism.

A drug made to treat memory loss seems to help those with Fragile X, a genetic disease that causes intellectual disability and autism. The drug improved language and learning in 30 men with Fragile X.

An artist and a brain scientist are working together to reduce the stigma surrounding addiction. Both are determined to change society's view of addiction.

At an animal sanctuary in the Congo, young students are learning why the gentle, endangered apes known as bonobos should be seen as a national treasure.

In the Democratic Republic of the Congo, there's an effort to save one of humankind's closest living relatives: the bonobo. This benefits the animals, brain research and the economy of the DRC.